Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million

  • Regeneron Pharmaceuticals said it will acquire substantially all of 23andMe's assets for $256 million after coming out on top at a bankruptcy auction for the once-sizzling DNA-testing startup.